OMNIGENETICA
Platform Solutions Evidence Company

Inform · Module 02

Pharmacogenomic decision-support, established once.

A patient’s lifetime pharmacogenomic profile across 100+ medications and 15+ drug classes — available at the point of every prescription.

Pharmacogenomic decision-support, established once, used every prescription.

01

100+ medications, 15+ drug classes

A pharmacogenomic profile covering high-impact medications across cardiology, oncology, psychiatry, anticoagulation, and pain management.

02

Right medication, right dose

Genotype-driven guidance on which medication and what dose, replacing trial-and-error prescribing with precision-medicine recommendations.

03

Actionable alternative-medication guidance

Where a patient’s genotype suggests reduced efficacy or elevated risk, alternative medications and dosage adjustments are surfaced at the point of care.

04

Adverse-event reduction

Pre-emptive PGx testing has been shown in published clinical literature to materially reduce adverse drug reactions across high-risk drug classes.

05

Adaptive updates

Recommendations refresh as new pharmacogenomic evidence is published, so a patient’s lifetime profile stays current without re-testing.

06

Reports for clinicians and patients

Clinician-grade variant interpretation paired with patient-facing summaries explaining what each finding means for medication choices.

Inform module specifications.

Capability
Specification
Medications covered
100+
PGx catalog
Drug classes covered
15+
PGx catalog
Pharmacogenetic variants tested
Comprehensive
Sequencing pipeline
Updates as evidence emerges
Continuous
Operational
Patient-facing summary included
Yes
Report design